News
VRNA
--
0.00%
--
PDE Inhibitors Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Apr 02, 2021 (Market Insight Reports) -- The report on PDE Inhibitors provides the clients with a comprehensive analysis of crucial driving factors, consumer...
Market Insight Reports · 04/02 09:47
PDE Inhibitors Market Development, Trends, Huge Demand, Growth Analysis and Forecasts 2020-2027 |Ameco Research
Comserve · 03/25 07:27
Verona Pharma Files for $250 Million Mixed-Securities Shelf
MT Newswires · 03/22 03:28
Verona Pharma Awarded U.S. Patent 10,945,950 'Liquid inhalation formulation comprising RPL554'
The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl- )-3,4,6,7-t...
Benzinga · 03/16 11:35
8-K: Verona Pharma plc
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/02 20:59
Lisa Deschamps Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined t...
GlobeNewswire · 03/02 07:00
The impact of COVID-19 on Drugs for Chronic Cough Market Size Estimation, Industry Share, Business Analysis, Growth Opportunities And Important Aspects By 2026
Mar 02, 2021 (The Expresswire) -- The report provides revenue of the globalDrugs for Chronic Cough Market for the period 2016 and 2026, considering 2020 as...
The Express Wire · 03/02 06:48
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and Presi...
GlobeNewswire · 03/01 07:00
Verona Pharma Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Verona Pharma Plc (NASDAQ:VRNA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 2:00 PM Eastern Time.
ACCESSWIRE · 02/25 17:20
10-K: VERONA PHARMA PLC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 02/25 13:32
8-K: Verona Pharma plc
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 12:32
Verona Pharma EPS beats by $0.30
Verona Pharma (VRNA): Q4 GAAP EPS of -$0.05 beats by $0.30.Cash and cash equivalents of $188M.Press Release
Seekingalpha · 02/25 07:26
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Positive Phase 2 results with pMDI ensifentrine in COPD
GlobeNewswire · 02/25 07:00
Verona Pharma's Q4 Loss Narrows, Operating Expenses Rise
MT Newswires · 02/25 03:44
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth q...
GlobeNewswire · 02/18 07:00
Wedbush Reaffirms Their Buy Rating on Verona Pharma (VRNA)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma (VRNA), with a price target of $25.00. The company's
SmarterAnalyst · 02/03 13:35
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
LONDON and RALEIGH, N.C., Feb 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under...
GlobeNewswire · 02/02 11:17
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit "µg" were mistakenly represented as "mg." The corrected re...
GlobeNewswire · 02/02 11:17
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit "ug" were mistakenly represented as "mg." The corrected release follows:
GlobeNewswire · 02/02 11:16
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
Benzinga · 02/02 10:11
Webull provides a variety of real-time VRNA stock news. You can receive the latest news about Verona Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VRNA
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company is developing ensifentrine, the treatment for respiratory disease. Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. In addition to nebulized ensifentrine, the Company has developed dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations of ensifentrine for less severe patients. The Company’s subsidiaries include Verona Pharma Inc. and Rhinopharma Limited.